Journal
VACCINE
Volume 26, Issue 38, Pages 4918-4926Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.07.018
Keywords
vaccine; cancer; polyclonal antibodies
Categories
Ask authors/readers for more resources
Up to now clinical experiences focusing EGF receptor, an attractive target for cancer therapy, have been limited to passive therapies, suggesting that therapeutic cancer vaccines inducing anti-epidermal growth factor receptor (EGFR) antibodies could also Work. Here, the humoral immune response induced in mice With a Vaccine formulation containing the human EGFR-extracellular domain and very small-sized proteoliposomes (VSSP), a novel nanoparticulated adjuvant was assessed. in vaccinated mice sera average of the specific polyclonal antibodies (PAb) titers was 10 (5). Anti-EGFR PAb were able to bind EGFR+ tumor cell lines, expressing different levels of the molecule. Noteworthy, the presence of Cetuximab only partially inhibited the vaccine-induced antibodies binding to H125 cells. Anti-EGFR PAb abrogated ligands-dependent EGFR phosphorylation, provoking tumor cells apoptosis. The described EGFR-based vaccine might be a superior therapeutic approach for patients with EGFR+ tumors. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available